Transcatheter Arterial chemoembolization for liver cancer: Is it time to distinguish conventional from drug-eluting chemoembolization?

Eleni Liapi, Jean Francois H. Geschwind

Research output: Contribution to journalReview article

Abstract

Conventional transcatheter arterial chemoembolization and chemoembolization with drug-eluting beads are increasingly being performed interchangeably in many institutions throughout the world. As both therapies continue to being tested in many phase II and III studies and in combination with other therapies, especially targeted agents, for treatment of primary and metastatic liver cancer, it is imperative to review their current status and evaluate their impact on patient survival. This review critically assesses patient selection, indications, contraindications, techniques, materials, safety, and clinical outcomes of patients treated with conventional chemoembolization and chemoembolization with drug-eluting beads.

Original languageEnglish (US)
Pages (from-to)37-49
Number of pages13
JournalCardiovascular and Interventional Radiology
Volume34
Issue number1
DOIs
StatePublished - Feb 1 2011

Keywords

  • Chemoembolization
  • Interventional radiology
  • Liver cancer

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Transcatheter Arterial chemoembolization for liver cancer: Is it time to distinguish conventional from drug-eluting chemoembolization?'. Together they form a unique fingerprint.

  • Cite this